Shanghai Fosun Pharmaceutical (02196) subsidiary HENLIUS has signed a framework cooperation agreement and reached a licensing agreement with Sandoz AG.

Shanghai Fosun Pharmaceutical (02196) announced that its controlling subsidiary HENLIUS has signed a Cooperation Framework Agreement with Sandoz AG, allowing for licensing cooperation related to registration, commercialization, development, and production in overseas regions for up to 10 monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components (referred to as "Cooperative Products"). Specific commercial terms have been reached for the first batch of three cooperative products (namely HLX05-N, HLX16, and the biosimilar Beiluizumab), and Sandoz AG has been granted an option for one potential cooperative product (namely HLXTE-HAase1001). For the first batch of three cooperative products, HENLIUS may receive up to $314 million in upfront fees, development milestone payments, and sales milestone payments, contingent on the corresponding research and development, regulatory approvals, and sales progress. The objective of this collaboration is to leverage the respective strengths and resources of both parties in research and development, production, and commercialization, continuously enhancing the accessibility and influence of the group's products in international markets while providing more treatment options for patients worldwide.